BB 3497

Drug Profile

BB 3497

Latest Information Update: 03 Jan 2002

Price : $50

At a glance

  • Originator British Biotech
  • Class Antibacterials
  • Mechanism of Action Peptide deformylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 03 Jan 2002 Discontinued-Preclinical for Bacterial infections in United Kingdom (Unknown route)
  • 16 Oct 2001 An in vitro study has been added to the Bacterial Infections antimicrobial activity section
  • 26 Sep 2000 Preclinical development for Bacterial infections in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top